Breaking News
0

Astellas Pharma Inc (ALPMY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.42 +0.05    +0.31%
13/11 - Closed. Currency in USD ( Disclaimer )
After Hours
16.42
0.00
0.00%
15:53:15 - Delayed Data
Type: Equity
Market: United States
ISIN: US04623U1025 
S/N: 04623U102
  • Volume: 206,228
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.32 - 16.44
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider
Astellas Pharma Inc 16.42 +0.05 +0.31%
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider

Astellas Pharma Inc Company Profile

 
Get an in-depth profile of Astellas Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryMajor Drugs
SectorHealthcare
Employees

16243

Equity Type

ADR

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

Contact Information

Phone +81-3-32443000
Fax -

Top Executives

Name Age Since Title
Yoshitsugu Shitaka - - Executive Officer, President of Subsidiary
Takuya Oshida - 2016 Executive Officer, Chief Director of Medical Affairs
Kazuhiro Sako - - Executive Officer, President of Subsidiary
Fumiaki Sakurai - 2018 Executive Officer
Taiji Sawamoto - 2017 Executive Officer, Director of Research Program Promotion in Main Research Unit
Hideki Shima - 2017 Executive Officer, Director of Technology Planning in Main Pharmaceutical Technology Unit
Yasuhiro Kanzaki - 2016 Executive Officer, Manager of Osaka Office in Main Sales Unit
Yukio Matsui - 2018 Executive Officer
Eisuke Nozawa - - Executive Officer, Director of Pharmaceutical Affairs
Naoki Okamura - 2018 Executive Officer
Tadashi Hara - 2017 Executive Officer, Director of Sales Strategy in Main Sales Unit
Masaaki Hirano - - Executive Officer, Director of Business Planning
Yoshihiko Hatanaka 62 2018 Chairman of the Board, Chairman of the Board of Directors, Representative Director
Mitsunori Matsuda - 2017 Senior Executive Officer, Chief Director of Pharmaceutical Technology
Chikashi Takeda - 2018 Senior Executive Officer
Masatoshi Kuroda - 2017 Senior Executive Officer, Chief Director of Asia & Oceania Business
Atsushi Kamide - 2018 Senior Executive Officer, Director of External Affairs
Akihiko Iwai - 2018 Senior Executive Officer, Chief Director of Research
Nobuaki Tanaka - 2018 Senior Executive Officer, Chief Director of Sales
Kenji Yasukawa 58 2018 President, Chief Executive Officer, Representative Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALPMY Comments

Write your thoughts about Astellas Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email